GlassScriptPhysician profile
Asna Amin
NPI 1649474925
$8,055.87
in general payments reported to CMS, 2019-2025
24 companies · $6,101 in 2025
The $6,101 reported for 2025 was more than what 90% of Colon & Rectal Surgery providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,201 · 2021: $161 · 2022: $227 · 2023: $218 · 2024: $147 · 2025: $6,101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Travel and Lodging: $1,369 · Food and Beverage: $1,097.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Travel and Lodging | $1,369.41 |
| Food and Beverage | $1,097.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,685.81 | 2021-2025 | |
| Medical Device Business Services, INC. | $1,201.16 | 2019 | |
| Janssen Biotech, INC. | $287.91 | 2022-2025 | Tremfya, Erleada |
| Ethicon US, LLC | $190.94 | 2021-2025 | Echelon Flex, Echelon Circular, Stratafix |
| Integra Lifesciences Corporation | $89.78 | 2022-2024 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Medtronic, INC. | $62.72 | 2022-2025 | Progrip, Transorb |
| Organon LLC | $61.09 | 2023 | Renflexis, Hadlima |
| Vertex Pharmaceuticals Incorporated | $59.15 | 2025 | |
| Smith+Nephew, INC. | $53.73 | 2024 | Collagenase Santyl |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.60 | 2022-2023 | Xifaxan, Plenvu |
| Olympus America INC. | $32.69 | 2023 | Olympus, Visera Elite II Video System Center, Endoeye Flex 3d Deflectable Videoscope |
| Antares Pharma, INC. | $32.27 | 2021 | |
| Heron Therapeutics, INC. | $31.51 | 2021-2024 | Zynrelef |
| Amgen INC. | $30.95 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $28.51 | 2025 | Orgovyx |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| 180 Medical, INC. | $23.49 | 2022 | |
| Mindray Ds USA, INC. | $21.74 | 2022 | |
| Kerecis Limited | $20.69 | 2021 | |
| Convatec INC. | $20.16 | 2024 | |
| Braintree Laboratories, INC. | $18.60 | 2023 | Sutab, Suflave |
| Merck Sharp & Dohme LLC | $18.42 | 2024 | Bridion |
| Takeda Pharmaceuticals U.S.A., INC. | $14.97 | 2021 | |
| Octapharma USA, INC. | $14.13 | 2023 | Octagam Immune Globulin (Human) |
| E.R. Squibb & Sons, L.L.C. | $13.85 | 2023 | Eliquis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asna Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.